C4 Therapeutics (CCCC) Current Deferred Revenue (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Current Deferred Revenue of $10.1 million for Q1 2026, down 53.1% year-over-year from $21.6 million in Q1 2025, and down 18.96% quarter-over-quarter from $12.5 million in Q4 2025.
C4 Therapeutics (CCCC) Current Deferred Revenue (2019 - 2026) Analysis & Trends
C4 Therapeutics' Current Deferred Revenue history runs 8 years deep, the most recent figure standing at $10.1 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 53.1% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at $10.1 million (down 53.1% YoY), while the FY2025 annual figure was $12.5 million, down 33.24% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $10.1 million, down from $12.5 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $43.8 million in Q2 2025, with the low at $8.4 million in Q3 2023.
- The 5-year median for Current Deferred Revenue is $22.2 million (2022), against an average of $25.6 million.
- The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue slumped 75.86% in 2023, then soared 146.55% in 2024.
- C4 Therapeutics' Current Deferred Revenue stood at $33.5 million in 2022, then tumbled by 53.84% to $15.5 million in 2023, then rose by 20.95% to $18.7 million in 2024, then slumped by 33.24% to $12.5 million in 2025, then decreased by 18.96% to $10.1 million in 2026.
- Business Quant data shows CCCC's Current Deferred Revenue at $10.1 million in Q1 2026, $12.5 million in Q4 2025, and $37.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.38 Mn |
| Mar 31, 2026 | 10.12 Mn |
| Dec 31, 2025 | 12.49 Mn |
| Sep 30, 2025 | 37.01 Mn |
| Jun 30, 2025 | 43.77 Mn |
| Mar 31, 2025 | 21.59 Mn |
| Dec 31, 2024 | 18.71 Mn |
| Sep 30, 2024 | 20.77 Mn |
| Jun 30, 2024 | 36.59 Mn |
| Mar 31, 2024 | 35.14 Mn |
| Dec 31, 2023 | 15.47 Mn |
| Sep 30, 2023 | 8.42 Mn |
| Jun 30, 2023 | 38.62 Mn |
| Mar 31, 2023 | 14.94 Mn |
| Dec 31, 2022 | 33.51 Mn |
| Sep 30, 2022 | 34.89 Mn |
| Jun 30, 2022 | 22.17 Mn |
| Mar 31, 2022 | 31.27 Mn |
| Dec 31, 2021 | 56.17 Mn |
| Sep 30, 2021 | 32.29 Mn |